FMC stock trades at EUR 39.36 as Korangy starts as CEO

On October 7, 2026, Fresenius Medical Care announced that Shervin J. Korangy would become chief executive officer and chair of the management board effective October 12, 2026, succeeding Helen Giza, according to the company’s press release. The company said its FME25+ transformation program reduced its cost base by around EUR 1.2 billion.

FMC stock was at EUR 39.36 in weekend trading at Lang & Schwarz on October 18, 2026, at 6:02 p.m. CEST. The bid was EUR 39.19 and the ask was EUR 39.52. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of FMC stock.

Market context: Market report DAX.

The week in figures

The Lang & Schwarz weekend-trading indication for October 18, 2026 was EUR 39.36 at 6:02 p.m. CEST. The quote was separate from the company’s leadership announcement.

Chronology of the week

On October 7, 2026, Fresenius Medical Care said its Supervisory Board had unanimously appointed Shervin Korangy as CEO and chair of the management board effective October 12, 2026. Korangy resigned from the company’s Supervisory Board in connection with the appointment, according to the EQS disclosure.

On October 12, 2026, the leadership change took effect. The company’s release said the next phase would focus on long-term profitable growth, innovation and strengthening its market position.

Dates of the coming week

The next Xetra session is scheduled for October 19, 2026. Fresenius Medical Care’s next quarterly financial report is scheduled for November 3, 2026, according to the company’s event information published with the EQS disclosure.